Guideline: Molecular Testing and Biomarkers

Selection of Germline Genetic Testing Panels in Patients with Cancer

Guideline Status: Current

Published Online: May 17, 2024

Last Updated: May 20, 2024

Published online ahead of print May 17, 2024. DOI: 10.1200/JCO.24.0062

Nadine Tung, Charite Ricker, Hans Messersmith, Judith Balmaña, Susan Domchek, Elena Martinez Stoffel, Khaldoun Almhanna, Banu Arun, Yanin Chavarri-Guerra, Stephanie A. Cohen, Deborah Cragun, Katherine D. Crew, Michael J. Hall, Gregory Idos, Ghecemy Lopez, Tuya Pal, Sara Pirzadeh-Miller, Colin Pritchard, Huma Q. Rana, Umang Swami, and Gregory A. Vidal

Purpose

To guide use of multigene panels for germline genetic testing for patients with cancer.

Methods

An ASCO Expert Panel convened to develop recommendations on the basis of a systematic review of guidelines, consensus statements, and studies of germline and somatic genetic testing.

Results

Fifty-two guidelines and consensus statements met eligibility criteria for the primary search; 14 studies were identified for Clinical Question 4.

Recommendations

Patients should have a family history taken and recorded that includes details of cancers in first- and second-degree relatives and the patient’s ethnicity. When more than one gene is relevant based on personal and/or family history, multigene panel testing should be offered. When considering what genes to include in the panel, the minimal panel should include the more strongly recommended genes from Table 1 and may include those less strongly recommended. A broader panel may be ordered when the potential benefits are clearly identified, and the potential harms from uncertain results should be mitigated. Patients who meet criteria for germline genetic testing should be offered germline testing regardless of results from tumor testing. Patients who would not normally be offered germline genetic testing based on personal and/or family history criteria but who have a pathogenic or likely pathogenic variant identified by tumor testing in a gene listed in Table 2 under the outlined circumstances should be offered germline testing.

© 2024 American Society of Clinical Oncology, all rights reserved. For licensing opportunities, contact licensing@asco.org

Please direct any requests to reuse ASCO Guidelines and/or related materials to permissions@asco.org.

Guideline Disclaimer

The Clinical Practice Guidelines and other guidance published herein are provided by the American Society of Clinical Oncology, Inc. (ASCO) to assist providers in clinical decision making. The information herein should not be relied upon as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of medical care. Further, the information is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. Recommendations specify the level of confidence that the recommendation reflects the net effect of a given course of action. The use of words like “must,” “must not,” “should,” and “should not” indicates that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. ASCO does not endorse third party drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions. Any use of a brand or trade name is for identification purposes only. ASCO provides this information on an “as is” basis and makes no warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information, or for any errors or omissions.